Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
Translational Oncology|January 5, 2021
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformationBrendan P Hodkinson, Michael Schaffer, Joshua D Brody, et al.
British Journal of Haematology|December 11, 2002
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortalitySuparno Chakrabarti, Irit Avivi, Stephen Mackinnon, et al.
Thrombosis Journal|November 5, 2021
Low FXIII activity levels in intensive care unit hospitalized COVID-19 patientsYael Lichter, Tanya Badelbayov, Irina Shalev, et al.
Acta Haematologica|October 15, 2019
Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and ApixabanMerav Barzilai, Ilya Kirgner, Arza Steimatzky, et al.
Annals of Hematology|June 22, 2022
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experienceOfrat Beyar-Katz, Chava Perry, Yael Bar On, et al.
European Journal of Haematology|October 17, 2022
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter studyLiat Shargian, Odelia Amit, Hanna Bernstine, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life StudyEfrat Luttwak, Moshe E Gatt, Eyal Lebel, et al.
Annals of Hematology|March 21, 2020
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry studyYael C Cohen, Hila Magen, Noa Lavi, et al.
Journal of Personalized Medicine|August 27, 2021
Feasibly of CD24/CD11b as a Screening Test for Hematological MalignanciesShiran Shapira, Dina Kazanov, Fatin Mdah, et al.
European Journal of Haematology|April 2, 2015
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessmentMoshe E Gatt, Izhar Hardan, Evgeni Chubar, et al.
Pageof 20